Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease
Article first published online: 14 OCT 2005
Alimentary Pharmacology & Therapeutics
Volume 22, Issue 9, pages 775–782, November 2005
How to Cite
BASTIDA, G., NOS, P., AGUAS, M., BELTRÁN, B., RUBÍN, Á., DASÍ, F. and PONCE, J. (2005), Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 22: 775–782. doi: 10.1111/j.1365-2036.2005.02636.x
- Issue published online: 14 OCT 2005
- Article first published online: 14 OCT 2005
- Accepted for publication 20 July 2005
Background : The incidence of thiopurine-induced hepatotoxicity in patients with inflammatory bowel disease varies in different studies.
Aims : To assess the rate of thiopurine-induced liver toxicity in patients with inflammatory bowel disease; to determine the predictive factors and to characterize its clinical course and management.
Methods : A cohort of 161 patients was prospectively followed for a median of 271 days. Hepatotoxicity was established when alanine transaminase or alkaline phosphatase plasma levels were greater than twice the upper normal limit.
Results : Abnormal liver function was detected in 21 patients (13%; 95% CI: 7–18). Hepatotoxicity occurred in 16 patients (10%; 95% CI: 6–16) after a median of 85 days. In five cases, treatment was withdrawn due to hepatotoxicity. Use of corticosteroids was associated with hepatotoxicity (OR: 4.94; 95% CI: 1.01–23.98) with antitumour necrosis factor concomitant therapy showing a protective role (OR: 0.3; 95% CI: 0.1–3.1). γ-Glutamyl transferase plasma levels at the onset of hepatotoxicity showed the best predictive value for treatment withdrawal (area under the receiver operating characteristic curve: 0.95).
Conclusions : The incidence of hepatotoxicity in inflammatory bowel disease patients receiving thiopurines is relevant, mainly in patients co-treated with corticosteroids. γ-Glutamyl transferase plasma level is a useful biomarker in therapy withdrawal prediction.